MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why ABVC Stock dropped -4.59% Today — RQD Quant Desk Flash
$1.04 -4.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.03
ABVC BioPharma Inc. (ABVC) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $27.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.03 (-1.02%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABVC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY ABVC SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)
FRED Regime × Technicals: 14% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.00-8% Next Q
26
Q2 (-2Q)Grade E$0.92+13% Next Q
29
Q3 (-1Q)Grade E$1.04+0% Next Q
31
CurrentGrade E$1.04-8.7% Hist 90D α
34
Trajectory: E (26) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ABVC Turnaround Squeeze
While ABVC currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.99) and Max Pain ($1.09) forces dealer call-delta covering toward $3.21.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABVC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABVC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ABVC Stock dropped -4.59% Today — RQD Quant Desk Flash
ABVC BioPharma Inc. (ABVC) dropped -4.59% to $1.04, trading at 14% of its 52-week range ($0.71 – $3.06). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 14% of its 52-week range ($0.71 – $3.06) with RSI-14 at 48.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.04 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ABVC Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABVC)
- ✓Walkthrough of ABVC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ABVC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.97%⚡ TESTING RESISTANCE
2026-10-30O $1.02H $1.04L $1.00C $1.04VOL 20.0K
RES: $1.13SUP: $0.93SMA50: $0.99SMA200: $1.26
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ABVC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ABVC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ABVC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABVC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABVC)
Health Care Rank #852 of 1016
⚔️ CPHI vs ABVC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ABVC vs. CPHI, CELU, BCTX, CRVO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ABVC BioPharma Inc. (ABVC) ranks #852 by composite RQD confidence (34/100, grade E) and #813 by equity capitalization ($27.8M). Within this direct 5-issuer industry benchmark cohort, ABVC leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. CPHI currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with ABVC at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ABVC
ACTIVE
ABVC BioPharma Inc. | E | 34/100 | — | — | -35.0% | -4.59% | $27.8M | Benchmark Subject |
| CPHI China Pharma Holdings Inc. | D | 45/100 | — | -3.2% | -11.4% | +4.84% | $28.0M | /cphi-vs-abvc → |
| CELU Celularity Inc. (Class A) | E | 34/100 | — | 24.4% | -35.0% | -9.66% | $27.6M | /celu-vs-abvc → |
| BCTX BriaCell Therapeutics Corp. | D- | 41/100 | — | — | — | -5.43% | $28.9M | /bctx-vs-abvc → |
| CRVO CervoMed Inc. | E | 29/100 | — | — | -35.0% | -20.81% | $26.5M | /crvo-vs-abvc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001173313In its most recent audited fiscal period (FY2025, filed 2025-12-31), ABVC BioPharma Inc. (ABVC) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $509.6K , and -100.0% cumulative change since FY2023) , GAAP net income of -$7.9M, operating cash flow of -$3.0M, and free cash flow of -$3.0M (-65.1% YoY). On the balance sheet, ABVC closed FY2025 with $21.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$7.9M | -$3.0M | -$3.0M | $21.1M | — |
| FY2024 (FY) | 2024-12-31 | $509.6K | -$4.9M | -$1.8M | -$1.8M | $7.5M | — |
| FY2023 (FY) | 2023-12-31 | $152.4K | -$7.8M | -$4.2M | -$4.2M | — | — |
3. ABVC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ABVC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, ABVC BioPharma Inc. (NASDAQ: ABVC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.04 (-4.59% 1D, market cap $27.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABVC ranks #852 in composite RQD confidence.
How does ABVC compare to CPHI and CELU in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABVC carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CPHI (China Pharma Holdings Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -11.4%, cap $28.0M) and CELU (Celularity Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $27.6M). Among the 5-stock peer group, ABVC leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ABVC?
Per ABVC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001173313), ABVC BioPharma Inc. generated $0 in revenue (-100.0% YoY), -$7.9M in net income, and -$3.0M in free cash flow against $21.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ABVC trading relative to its 50-day, 200-day, and 52-week technical levels?
ABVC last traded at $1.04 (-4.59% on volume of 34,884 shares), positioning the stock +5.05% above its 50-day simple moving average ($0.99) and -17.46% below its 200-day simple moving average ($1.26). Across its 52-week range of $0.71 to $3.06, ABVC sits at the 14.0% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.17).
ABVC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ABVC stock moving today?
Why ABVC Stock dropped -4.59% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.